Navigation Links
Global Cytomegalovirus Retinitis Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, Hospira and Shire
Date:8/26/2014

DUBLIN, Aug. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering.

Cytomegalovirus retinitis is a viral eye inflammation of the retina. The causative organism of this disease is cytomegalovirus, a herpes virus that attacks the photosensitive cells in the retina. This disease can lead to permanent blindness if left untreated. It affects one eye initially but spreads to the other eye if neglected. The virus is very commonly found in humans but stays dormant. It usually affects a person with weakened immune system such as HIV-positive patients. There are two forms of cytomegalovirus retinitis: indolent form and fulminant form. Some of the common symptoms of cytomegalovirus retinitis are blurred vision, seeing floaters, photophobia, and blind spots.

The analysts forecast the Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis.

The report, the Global Cytomegalovirus Retinitis market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cytomegalovirus Retinitis market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

An increase in combination therapies for the treatment of cytomegalovirus retinitis is a major trend emerging in the market. These therapies lower drug resistance in patients and ensure more effective action of the drug.

According to the report, the Global Cytomegalovirus Retinitis market is experiencing a large number of unmet needs. Currently, Roche's Valcyte is the only branded drug available for the treatment of this indication. The market has also observed the use of off-label drugs for the treatment of cytomegalovirus retinitis.

Further, the report states that one of the major challenges in the market is a lack of approved treatment guidelines by the WHO, which is responsible for the negligence of the treatment of cytomegalovirus retinitis worldwide.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Market Segmentation by Route of Administration

08. Market Segmentation by Dosage Form

09. Market Assessment of Valcyte

10. Rate of Incidence and Prevalence

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

20. Key Vendor Analysis

21. Other Reports in this Series

Companies Mentioned:

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Hospira
  • Shire
  • Auritec Pharmaceuticals
  • Chimerix Pharmaceuticals
  • Isis Pharmaceuticals
  • pSivida
  • Sanofi

For more information visit http://www.researchandmarkets.com/research/sp3krb/global

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis
2. MNX Global Logistics renews multi-year contract with NuVasive, Inc.
3. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
4. Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference
5. Cardiomyopathy Global Clinical Trials Review, H2, 2014
6. Vascular Dementias Global Clinical Trials Review, H2, 2014
7. Vocal Cord Paralysis Global Clinical Trials Review, H2, 2014
8. Traumatic Pain Global Clinical Trials Review, H2, 2014
9. Traumatic Spinal Cord Injury Global Clinical Trials Review, H2, 2014
10. Tremor Global Clinical Trials Review, H2, 2014
11. Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):